


Characteristic & Category levels & Switch proportion & P-value\\
\hline
 & PCV7 vs NoVax & 80.0\% & \\
\cline{2-3}
 & PCV10 vs NoVax & 84.4\% & \\
\cline{2-3}
 & PCV13 vs NoVax & 71.4\% & \\
\cline{2-3}
\multirow[t]{-4}{*}{\raggedright\arraybackslash Type of comparison} & PCV13 vs PCV10 & 53.8\% & \multirow[t]{-4}{*}{\raggedleft\arraybackslash 0.080}\\
\cline{1-4}
 & Low & 78.6\% & \\
\cline{2-3}
 & Lower-middle & 85.7\% & \\
\cline{2-3}
\multirow[t]{-3}{*}{\raggedright\arraybackslash Income group} & Upper-middle & 74.0\% & \multirow[t]{-3}{*}{\raggedleft\arraybackslash 0.506}\\
\cline{1-4}
 & Excluded & 81.3\% & \\
\cline{2-3}
\multirow[t]{-2}{*}{\raggedright\arraybackslash Herd effects} & Included & 64.1\% & \multirow[t]{-2}{*}{\raggedleft\arraybackslash 0.045}\\
\cline{1-4}
 & Excluded & 76.0\% & \\
\cline{2-3}
\multirow[t]{-2}{*}{\raggedright\arraybackslash Serotype replacement} & Included & 82.4\% & \multirow[t]{-2}{*}{\raggedleft\arraybackslash 0.763}\\
\cline{1-4}
 & Healthcare/payer & 75.0\% & \\
\cline{2-3}
\multirow[t]{-2}{*}{\raggedright\arraybackslash Study perspective} & Societal & 79.0\% & \multirow[t]{-2}{*}{\raggedleft\arraybackslash 0.693}\\
\hline

